Centre proposes faster approvals for eligible drug studies and import test licences
The Centre has proposed prior intimation instead of approval for eligible domestic BA/BE studies and a cut in new-drug import test-licence processing time to 45 working days from 90. High-risk categories would continue to require formal licences.
What happened
retail-company · Centre proposes allowing prior intimation rather than approval for eligible domestic drug BA/BE studies, while cutting new-drug import test
Key facts
- 90 working days
- 45 working days
- Rules 67, 68, 69 and 70
- New Drugs and Clinical Trials Rules 2019
Why this matters
Pharma companies may find Indian clinical research, testing and licensing partnerships more attractive, while high-risk products remain subject to full approval requirements.
What to watch
- Publication of final rules versus the consultation draft
- Eligibility thresholds and list of excluded high-risk categories
- Actual regulator turnaround data after rollout
- Growth in BA/BE-study filings and import test-licence applications
- Capacity utilization and pricing at CROs, bioanalytical labs and reference-product importers
- Increase in generic product launches and competitor counts in affected therapy areas
- Track the final notification, including the exact definition of eligible BA/BE studies, high-risk exclusions and implementation date.
- Prioritize pipeline molecules where BA/BE-study timing or imported reference-product testing is the critical launch bottleneck.
- Increase readiness at CRO, analytical-lab and regulatory-affairs teams to use prior intimation immediately after implementation.
- Reassess launch sequencing and inventory plans for generics likely to face earlier multi-player entry.
- For pharmacy retailers and distributors, prepare for faster SKU refreshes and potential procurement-cost reductions in high-volume generic categories.